Drug Profile
Research programme: peptide therapeutics - Genentech/PeptiDream
Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator PeptiDream
- Developer Genentech; PeptiDream
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Proto-oncogene protein c-met modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 07 Dec 2022 Early research is still ongoing for Undisclosed indication in Japan and USA (PeptiDream pipeline, December 2022)
- 20 Jul 2016 PeptiDream and Genentech enter into a technology collaboration agreement to discover and develop Peptide therapeutics
- 21 Dec 2015 PeptiDream and Genentech enter into a collaboration to discover and develop Peptide therapeutics